Cargando…

Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology

Corneal penetration is a key rate limiting step in the bioavailability of topical ophthalmic formulations that incorporate poorly permeable drugs. Recent advances have greatly aided the ocular delivery of such drugs using colloidal drug delivery systems. Ribavirin, a poorly permeable BCS class-III d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Mohamed Moustafa, Maria, Doaa Nabih, Wang, XiangDi, Simpson, Raven N., Hollingsworth, T.J., Jablonski, Monica M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463957/
https://www.ncbi.nlm.nih.gov/pubmed/32722550
http://dx.doi.org/10.3390/pharmaceutics12080704
_version_ 1783577253562548224
author Ibrahim, Mohamed Moustafa
Maria, Doaa Nabih
Wang, XiangDi
Simpson, Raven N.
Hollingsworth, T.J.
Jablonski, Monica M.
author_facet Ibrahim, Mohamed Moustafa
Maria, Doaa Nabih
Wang, XiangDi
Simpson, Raven N.
Hollingsworth, T.J.
Jablonski, Monica M.
author_sort Ibrahim, Mohamed Moustafa
collection PubMed
description Corneal penetration is a key rate limiting step in the bioavailability of topical ophthalmic formulations that incorporate poorly permeable drugs. Recent advances have greatly aided the ocular delivery of such drugs using colloidal drug delivery systems. Ribavirin, a poorly permeable BCS class-III drug, was incorporated in bioadhesive multiple W/O/W microemulsion (ME) to improve its corneal permeability. The drug-loaded ME was evaluated regarding its physical stability, droplet size, PDI, zeta potential, ultrastructure, viscosity, bioadhesion, in vitro release, transcorneal permeability, cytotoxicity, safety and ocular tolerance. Our ME possessed excellent physical stability, as it successfully passed several cycles of centrifugation and freeze–thaw tests. The formulation has a transparent appearance due to its tiny droplet size (10 nm). TEM confirmed ME droplet size and revealed its multilayered structure. In spite of the high aqueous solubility and the low permeability of ribavirin, this unique formulation was capable of sustaining its release for up to 24 h and improving its corneal permeability by 3-fold. The in vitro safety of our ME was proved by its high percentage cell viability, while its in vivo safety was confirmed by the absence of any sign of toxicity or irritation after either a single dose or 14 days of daily dosing. Our ME could serve as a vehicle for enhanced ocular delivery of drugs with different physicochemical properties, including those with low permeability.
format Online
Article
Text
id pubmed-7463957
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74639572020-09-04 Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology Ibrahim, Mohamed Moustafa Maria, Doaa Nabih Wang, XiangDi Simpson, Raven N. Hollingsworth, T.J. Jablonski, Monica M. Pharmaceutics Article Corneal penetration is a key rate limiting step in the bioavailability of topical ophthalmic formulations that incorporate poorly permeable drugs. Recent advances have greatly aided the ocular delivery of such drugs using colloidal drug delivery systems. Ribavirin, a poorly permeable BCS class-III drug, was incorporated in bioadhesive multiple W/O/W microemulsion (ME) to improve its corneal permeability. The drug-loaded ME was evaluated regarding its physical stability, droplet size, PDI, zeta potential, ultrastructure, viscosity, bioadhesion, in vitro release, transcorneal permeability, cytotoxicity, safety and ocular tolerance. Our ME possessed excellent physical stability, as it successfully passed several cycles of centrifugation and freeze–thaw tests. The formulation has a transparent appearance due to its tiny droplet size (10 nm). TEM confirmed ME droplet size and revealed its multilayered structure. In spite of the high aqueous solubility and the low permeability of ribavirin, this unique formulation was capable of sustaining its release for up to 24 h and improving its corneal permeability by 3-fold. The in vitro safety of our ME was proved by its high percentage cell viability, while its in vivo safety was confirmed by the absence of any sign of toxicity or irritation after either a single dose or 14 days of daily dosing. Our ME could serve as a vehicle for enhanced ocular delivery of drugs with different physicochemical properties, including those with low permeability. MDPI 2020-07-26 /pmc/articles/PMC7463957/ /pubmed/32722550 http://dx.doi.org/10.3390/pharmaceutics12080704 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ibrahim, Mohamed Moustafa
Maria, Doaa Nabih
Wang, XiangDi
Simpson, Raven N.
Hollingsworth, T.J.
Jablonski, Monica M.
Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology
title Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology
title_full Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology
title_fullStr Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology
title_full_unstemmed Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology
title_short Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology
title_sort enhanced corneal penetration of a poorly permeable drug using bioadhesive multiple microemulsion technology
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463957/
https://www.ncbi.nlm.nih.gov/pubmed/32722550
http://dx.doi.org/10.3390/pharmaceutics12080704
work_keys_str_mv AT ibrahimmohamedmoustafa enhancedcornealpenetrationofapoorlypermeabledrugusingbioadhesivemultiplemicroemulsiontechnology
AT mariadoaanabih enhancedcornealpenetrationofapoorlypermeabledrugusingbioadhesivemultiplemicroemulsiontechnology
AT wangxiangdi enhancedcornealpenetrationofapoorlypermeabledrugusingbioadhesivemultiplemicroemulsiontechnology
AT simpsonravenn enhancedcornealpenetrationofapoorlypermeabledrugusingbioadhesivemultiplemicroemulsiontechnology
AT hollingsworthtj enhancedcornealpenetrationofapoorlypermeabledrugusingbioadhesivemultiplemicroemulsiontechnology
AT jablonskimonicam enhancedcornealpenetrationofapoorlypermeabledrugusingbioadhesivemultiplemicroemulsiontechnology